Pherecydes Pharma Announces Its Participation in a Number of Major Scientific Conferences and Investor Events in H2 2021
08 September 2021 - 5:45PM
Business Wire
Regulatory News:
Pherecydes Pharma (FR0011651694 - ALPHE), a biotechnology
company specializing in precision phage therapy to treat resistant
and/or complicated bacterial infections, today announces that its
management team will participate in the following events over the
coming months:
September 16, 2021 (face-to-face or remote symposium) Pherecydes
Pharma will participate in this symposium dedicated to “Innovative
approaches in human, animal and environmental health in the fight
against antibiotic resistance” to present the advantages of
precision phage therapy. For more information, click here
- Boston Biotechnology Summit
September 30, 2021 (virtual summit) This summit was created in
2016 with the aim of supporting international cooperation between
health players in order to solve unmet medical needs. For more
information, click here
- Portzamparc Biotech / Healthcare Conference
October 6, 2021 (face-to-face, Paris) This event, organized by
Portzamparc, a subsidiary of the BNP Paribas Group, gives French
and international investors an opportunity to interact with the
heads of listed healthcare sector companies.
- “A day @ Bioaster” presentation
October 7, 2021 (face-to-face, Lyon) This event, organized by
Bioaster, a non-profit technology research institute in the field
of microbiology, will have as its central theme “The hope and
promise of precision medicine in infectious diseases”.
- European Midcap Event Paris
October 21-22, 2021 (face-to-face, Paris) One of the leading
investor forums, this event provides some 400 international
institutional investors with an opportunity to talk with the heads
of more than 150 listed companies. For more information, click
here
November 23, 2021 (Palais Brongniart, Paris) Over the last three
years, Investir Day has become a key event for shareholders,
investors and savers where they can spend an entire day accessing
numerous meetings, speeches and presentations and can meet with
heads of listed companies.
November 23-24, 2021 (congress in person, Brussels, Belgium) On
November 23, Dr. Cindy Fevre, Director of R&D at Pherecydes
Pharma, will speak on the topic “Clinical application of natural
phages in precision phage therapy: a concept applied to French
patients within the framework of a compassionate care program”.
About Pherecydes Pharma
Founded in 2006, Pherecydes Pharma is a biotechnology company
that develops treatments against resistant bacterial infections,
responsible for many serious infections. The Company has developed
an innovative approach, precision phage therapy, based on the use
of phages, natural bacteria-killing viruses. Pherecydes Pharma is
developing a portfolio of phages targeting 3 of the most resistant
and dangerous bacteria, which alone account for more than two
thirds of hospital-acquired resistant infections: Staphylococcus
aureus, Escherichia coli and Pseudomonas aeruginosa. The concept of
precision phage therapy has been successfully applied in more than
26 patients in the context of compassionate use, under the
supervision of the French National Agency for the Safety of
Medicines (ANSM). Headquartered in Nantes, Pherecydes Pharma has a
team of around twenty experts from the pharmaceutical industry,
biotechnology sector and academic research.
For more information, www.pherecydes-pharma.com
Disclaimer
This press release contains non-factual elements, including, but
not limited to, certain statements regarding future results and
other future events. These statements are based on the current
vision and assumptions of the management of the Company. They
incorporate known and unknown risks and uncertainties that could
result in significant differences in results, profitability and
expected events. In addition, Pherecydes Pharma, its shareholders
and its affiliates, directors, officers, counsels and employees
have not verified the accuracy of, and make no representations or
warranties about, statistical information or forecast information
contained within this news release and that originates or is
derived from third party sources or industry publications; these
statistical data and forecast information are only used in this
press release for information purposes. Finally, this press release
may be drafted in French and in English. In the event of
differences between the two texts, the French version will
prevail.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210908005840/en/
Pherecydes Pharma Philippe Rousseau CFO
investors@pherecydes-pharma.com
NewCap Dusan Oresansky Investor Relations
pherecydes@newcap.eu T.: +33 1 44 71 94 92
NewCap Nicolas Merigeau Media Relations
pherecydes@newcap.eu T.:
+33 1 44 71 94 98